Breast Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2023
 |
| Breast Cancer Therapeutics |
Albany, New York, Apr 18, 2017
"Breast
Cancer Therapeutics Market - Global Industry Analysis, Size, Share,
Growth, Trends, and Forecast 2017 - 2023"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
This
report on the breast cancer therapeutics market studies the current
as well as future prospects of the market globally. The stakeholders
of this report include pharmaceutical companies and intermediaries
engaged in the new drug discovery, pipeline development of various
breast cancer therapeutics as well as new entrants planning to enter
this market. This report comprises an elaborate executive summary
along with a market snapshot providing overall information of various
segments and sub-segments considered in the scope of the study. This
section also provides the overall information and data analysis of
the global breast cancer therapeutics market with respect to the
leading market segments in terms of geography.
The
global breast cancer therapeutics market has been studied based on
major drug class segments, and their regional as well as national
markets. Based on drug class, the global market has been categorized
into five major segments: HER2 inhibitors, mitotic inhibitors,
anti-metabolites, aromatase inhibitors, and hormone receptors. The
market for these segments and sub-segments has been extensively
analyzed based on their utility, effectiveness, sales, and geographic
presence. Market revenue in terms of US$ Mn and compound annual
growth rate (CAGR %) from 2017 to 2023 are provided for all segments,
considering 2014 as the base year.
The market overview section of the report explores
the market dynamics such as drivers, restraints, and opportunities
that currently have a strong impact on the breast cancer therapeutics
market and could influence the market in the near future. Market
attractiveness analysis has been provided in the market overview
section in order to explain the intensity of competition in the
market across different geographies. The competitive scenario among
different market players is illustrated through market share analysis
in the competitive landscape section of the report. All these factors
would help market players to take strategic decisions in order to
strengthen their positions and expand their shares in the global
market.
Geographically, the breast cancer therapeutics
market has been segmented into five regions: North America (the U.S.
and Canada), Europe (the U.K., Germany, and Rest of Europe), Asia
Pacific (Japan, South Korea, and Rest of APAC), Latin America (Brazil
and Rest of Latin America), and Middle East & Africa (MEA).
Market revenue in terms of US$ Mn and CAGR % from 2017 to 2023 are
provided for all the regions and countries, considering 2014 as the
base year.
The recommendations section included in the report
would assist existing market players in expanding their market shares
and new pharmaceutical companies in establishing their presence in
the global breast cancer market. The report also profiles leading and
emerging new players in the breast cancer therapeutics market based
on various attributes such as company overview, financial overview,
business strategies, product portfolio, and recent developments.
Major players profiled in this report include AstraZeneca plc, Eisai
Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd.,
GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., Puma
Biotechnology, Sanofi S.A., and Teva Pharmaceutical Industries Ltd.
** The global breast cancer therapeutics market
has been segmented as follows:
– Global Breast Cancer Therapeutics
Market, by Drug Class
- Overview
- Global HER2 Inhibitors Market Revenue, 2017
** Table of Contents
1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
2 Executive Summary
2.1 Global Breast Cancer Therapeutics: Market Snapshot
2.2 Global Breast Cancer Therapeutics Market Share, by Geography, 2014 & 2023(Value %)
2.3 Global Breast Cancer Therapeutics Market, by Drug Class, 2014 & 2023 (Value %)
2.1 Global Breast Cancer Therapeutics: Market Snapshot
2.2 Global Breast Cancer Therapeutics Market Share, by Geography, 2014 & 2023(Value %)
2.3 Global Breast Cancer Therapeutics Market, by Drug Class, 2014 & 2023 (Value %)
3 Global Breast Cancer Therapeutics Market
- Market Overview
3.1 Market Definition and Overview
3.2 Epidemiology & High Risk Groups
3.3 Diagnosis and Types of Breast Cancer
3.4 Other Breast Cancer Therapies
3.5 Market Dynamics
3.5.1 Drivers
3.5.1.1 Higher Incidence Rate
3.5.1.2 Demographic Transition
3.5.1.3 Rising Prevalence Of Obesity
3.5.1.4 Diagnostic Screening Programs
3.5.1.5 Increase in Private Health Insurance Plans:
3.5.2 Restraints
3.5.2.1 Generic Drugs: Substitute Branded Drugs
3.5.2.2 Intense Competition: Fall in Prices
3.5.2.3 Access barriers due to high drug costs
3.5.2.4 Absence of Social Health Insurance
3.5.2.5 Serious Side Effects of Breast Cancer Therapeutics
3.5.2.6 Countries Lacking Women Empowerment
3.5.3.7 Newer medication options
3.5.3 Opportunities
3.5.3.1 Potential Growth of Domestic Pharmaceutical Companies
3.5.3.2 Combination Drug Therapy
3.5.3.3 Technological Advancements and Robust Trends of Drug Approval
3.5.3.4 New Companion Diagnostics Models
3.5.3.5 Drug Therapy for Triple Negative (TNBC)
3.5.3.6 Approval for Multiple Indications (positive & negative types) HER2 breast cancer
3.7 Market Attractiveness Analysis– Breast Cancer Therapeutics Market, by Geography (2014) (%)
3.8 Competitive Landscape – Breast Cancer Therapeutics Market, by Key Players, 2014 (%)
3.1 Market Definition and Overview
3.2 Epidemiology & High Risk Groups
3.3 Diagnosis and Types of Breast Cancer
3.4 Other Breast Cancer Therapies
3.5 Market Dynamics
3.5.1 Drivers
3.5.1.1 Higher Incidence Rate
3.5.1.2 Demographic Transition
3.5.1.3 Rising Prevalence Of Obesity
3.5.1.4 Diagnostic Screening Programs
3.5.1.5 Increase in Private Health Insurance Plans:
3.5.2 Restraints
3.5.2.1 Generic Drugs: Substitute Branded Drugs
3.5.2.2 Intense Competition: Fall in Prices
3.5.2.3 Access barriers due to high drug costs
3.5.2.4 Absence of Social Health Insurance
3.5.2.5 Serious Side Effects of Breast Cancer Therapeutics
3.5.2.6 Countries Lacking Women Empowerment
3.5.3.7 Newer medication options
3.5.3 Opportunities
3.5.3.1 Potential Growth of Domestic Pharmaceutical Companies
3.5.3.2 Combination Drug Therapy
3.5.3.3 Technological Advancements and Robust Trends of Drug Approval
3.5.3.4 New Companion Diagnostics Models
3.5.3.5 Drug Therapy for Triple Negative (TNBC)
3.5.3.6 Approval for Multiple Indications (positive & negative types) HER2 breast cancer
3.7 Market Attractiveness Analysis– Breast Cancer Therapeutics Market, by Geography (2014) (%)
3.8 Competitive Landscape – Breast Cancer Therapeutics Market, by Key Players, 2014 (%)
4 Market Segmentation – By Drug
Class
4.1 Overview
4.2 Global HER2 Inhibitors Market Revenue, 2017–2023 (US$ Mn)
4.2.1 Herceptin (Trastuzumab)
4.2.2 Tykerb (Lapatinib)
4.2.3 Perjeta (Pertuzumab)
4.2.4 Kadcyla (Ado-trastuzumab emtansine)
4.3 Global Mitotic Inhibitors Market Revenue, 2017–2023 (US$ Mn)
4.3.1 Halaven (Eribulin)
4.3.2 Taxotere (Docetaxel)
4.3.3 Ixempra (Ixabepilone)
4.4 Global Anti-metabolites Market Revenue, 2017–2023 (US$ Mn)
4.4.1 Gemzar (Gemcitabine)
4.5 Global Aromatase Inhibitors Market Revenue, 2017–2023 (US$ Mn)
4.5.1 Femara (Leterozole)
4.5.2 Aromasin (Exemestane)
4.5.3 Arimidex (Anastrozole)
4.5.4 Ibrance (Palbociclib)
4.5.5 Afinitor (Everolimus)
4.6 Global Hormone Receptor Market Revenue, 2017–2023 (US$ Mn)
4.6.1 Zoladex
4.6.2 Faslodex
4.6.3 Fareston
4.1 Overview
4.2 Global HER2 Inhibitors Market Revenue, 2017–2023 (US$ Mn)
4.2.1 Herceptin (Trastuzumab)
4.2.2 Tykerb (Lapatinib)
4.2.3 Perjeta (Pertuzumab)
4.2.4 Kadcyla (Ado-trastuzumab emtansine)
4.3 Global Mitotic Inhibitors Market Revenue, 2017–2023 (US$ Mn)
4.3.1 Halaven (Eribulin)
4.3.2 Taxotere (Docetaxel)
4.3.3 Ixempra (Ixabepilone)
4.4 Global Anti-metabolites Market Revenue, 2017–2023 (US$ Mn)
4.4.1 Gemzar (Gemcitabine)
4.5 Global Aromatase Inhibitors Market Revenue, 2017–2023 (US$ Mn)
4.5.1 Femara (Leterozole)
4.5.2 Aromasin (Exemestane)
4.5.3 Arimidex (Anastrozole)
4.5.4 Ibrance (Palbociclib)
4.5.5 Afinitor (Everolimus)
4.6 Global Hormone Receptor Market Revenue, 2017–2023 (US$ Mn)
4.6.1 Zoladex
4.6.2 Faslodex
4.6.3 Fareston
5 Market Segmentation – By Geography
5.1 Introduction
5.2 Global Breast Cancer Therapeutics Market Revenue, 2017–2023 (US$ Mn)
5.3 North America Breast Cancer Therapeutics Market Revenue, 2017–2023 (US$ Mn)
5.3.1 U.S.
5.3.2 Canada
5.4 Europe Breast Cancer Therapeutics Market Revenue, 2017–2023 (US$ Mn)
5.4.1 Germany
5.4.3 U.K.
5.4.4 Rest of Europe
5.5 Asia Pacific Breast Cancer Therapeutics Market Revenue, 2017–2023 (US$ Mn)
5.5.1 Japan
5.5.2 South Korea
5.5.3 Rest of Asia Pacific
5.6 Rest of the World
5.6.1 Latin America
5.6.1.1 Brazil
5.6.1.2 Rest of Latin America
5.6.2 Middle East and Africa
5.1 Introduction
5.2 Global Breast Cancer Therapeutics Market Revenue, 2017–2023 (US$ Mn)
5.3 North America Breast Cancer Therapeutics Market Revenue, 2017–2023 (US$ Mn)
5.3.1 U.S.
5.3.2 Canada
5.4 Europe Breast Cancer Therapeutics Market Revenue, 2017–2023 (US$ Mn)
5.4.1 Germany
5.4.3 U.K.
5.4.4 Rest of Europe
5.5 Asia Pacific Breast Cancer Therapeutics Market Revenue, 2017–2023 (US$ Mn)
5.5.1 Japan
5.5.2 South Korea
5.5.3 Rest of Asia Pacific
5.6 Rest of the World
5.6.1 Latin America
5.6.1.1 Brazil
5.6.1.2 Rest of Latin America
5.6.2 Middle East and Africa
6 Recommendations
7 Company Profiles
7.1 AstraZeneca plc
7.2 Eisai Co., Ltd.
7.3 Eli Lilly and Company
7.4 F. Hoffmann-La Roche Ltd.
7.5 GlaxoSmithKline plc
7.6 Novartis International AG
7.7 Pfizer, Inc.
7.8 Puma Biotechnology, Inc.
7.9 Sanofi S.A.
7.1 AstraZeneca plc
7.2 Eisai Co., Ltd.
7.3 Eli Lilly and Company
7.4 F. Hoffmann-La Roche Ltd.
7.5 GlaxoSmithKline plc
7.6 Novartis International AG
7.7 Pfizer, Inc.
7.8 Puma Biotechnology, Inc.
7.9 Sanofi S.A.
Comments
Post a Comment